Arena Pharmaceuticals Stock Forecast, Price & News

Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

Is Arena Pharmaceuticals a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arena Pharmaceuticals stock.
View analyst ratings for Arena Pharmaceuticals or view top-rated stocks.

How has Arena Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Arena Pharmaceuticals' stock was trading at $40.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ARNA stock has increased by 42.1% and is now trading at $57.42.
View which stocks have been most impacted by COVID-19.

When is Arena Pharmaceuticals' next earnings date?

Arena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Arena Pharmaceuticals.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) posted its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($3.21) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($2.53) by $0.68. During the same period in the previous year, the company posted ($1.69) EPS.
View Arena Pharmaceuticals' earnings history.

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Arena Pharmaceuticals's stock reverse split on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ARNA?

9 equities research analysts have issued twelve-month price targets for Arena Pharmaceuticals' stock. Their forecasts range from $80.00 to $120.00. On average, they anticipate Arena Pharmaceuticals' share price to reach $99.56 in the next year. This suggests a possible upside of 73.4% from the stock's current price.
View analysts' price targets for Arena Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the following people:

• Amit Dilip Munshi, President, Chief Executive Officer & Director
• Laurie D. Stelzer, Chief Financial Officer & Executive Vice President
• Paul D. Streck, Chief Medical Officer & SVP-Clinical Development
• Douglas J. Manion, Executive Vice President-Research & Development
• Douglas A. Bakan, Vice President-Technical Operations

What is Amit Munshi's approval rating as Arena Pharmaceuticals' CEO?

16 employees have rated Arena Pharmaceuticals CEO Amit Munshi on Glassdoor.com. Amit Munshi has an approval rating of 66% among Arena Pharmaceuticals' employees.

Who are some of Arena Pharmaceuticals' key competitors?

Some companies that are related to Arena Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Incyte (INCY), Exact Sciences (EXAS), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of ARNA's competitors.

What other stocks do shareholders of Arena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), (CGC), Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Micron Technology (MU), NVIDIA (NVDA), Novavax (NVAX), Alibaba Group (BABA), GW Pharmaceuticals (GWPH) and AT&T (T).

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

Who are Arena Pharmaceuticals' major shareholders?

Arena Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (13.68%), BlackRock Inc. (8.68%), Goldman Sachs Group Inc. (2.33%), Janus Henderson Group PLC (2.03%), Geode Capital Management LLC (1.74%) and Bank of New York Mellon Corp (1.57%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Christopher Cabell, Jayson Donald Alexander Dallas, Kevin Robert Lind, Manmeet Singh Soni, Robert Lisicki, Robert Lisicki, Steven W Spector, Tina Susan Nova and Vincent Aurentz.
View institutional ownership trends for Arena Pharmaceuticals.

Which institutional investors are selling Arena Pharmaceuticals stock?

ARNA stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Assenagon Asset Management S.A., BlackRock Inc., Farallon Capital Management LLC, Wellington Management Group LLP, Dimensional Fund Advisors LP, Emerald Mutual Fund Advisers Trust, and Penserra Capital Management LLC. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Amit Munshi, Jayson Donald Alexander Dallas, Robert Lisicki, and Vincent Aurentz.
View insider buying and selling activity for Arena Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Arena Pharmaceuticals stock?

ARNA stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Suvretta Capital Management LLC, Goldman Sachs Group Inc., Segall Bryant & Hamill LLC, Moore Capital Management LP, Millennium Management LLC, Laurion Capital Management LP, and Pura Vida Investments LLC. Company insiders that have bought Arena Pharmaceuticals stock in the last two years include Amit Munshi, and Jayson Donald Alexander Dallas.
View insider buying and selling activity for Arena Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Arena Pharmaceuticals?

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $57.42.

How much money does Arena Pharmaceuticals make?

Arena Pharmaceuticals has a market capitalization of $3.51 billion and generates $320 thousand in revenue each year. The biopharmaceutical company earns $-404.73 million in net income (profit) each year or ($9.69) on an earnings per share basis.

How many employees does Arena Pharmaceuticals have?

Arena Pharmaceuticals employs 363 workers across the globe.

When was Arena Pharmaceuticals founded?

Arena Pharmaceuticals was founded in 1977.

What is Arena Pharmaceuticals' official website?

The official website for Arena Pharmaceuticals is www.arenapharm.com.

Where are Arena Pharmaceuticals' headquarters?

Arena Pharmaceuticals is headquartered at 6154 Nancy Ridge Drive, San Diego CA, 92121.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at (858) 453-7200, via email at [email protected], or via fax at 858-453-7210.